- #EASD26: Lilly’s amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes Endpoints News
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s CNBC
- Blockbuster retatrutide trial signals a ‘new high-water mark’ for weight-loss drugs Scientific American
- Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
- ‘Godzilla’ of weight-loss drugs could provide other important health benefits The Guardian